Comparison of Superdisintegrants in Orally Disintegrating Tablets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Comparison of Superdisintegrants in Orally Disintegrating Tablets
The functionality and performance of three types of commercial superdisintegrants were evaluated in the application of orally disintegrating tablets.


Pharmaceutical Technology
Volume 34, Issue 7, pp. 54-65

References

1. P. Van Arnum, Pharm. Technol. 31 (10), 68–76 (2007).

2. FDA, Draft Guidance for Industry: Orally Disintegrating Tablets (Rockville, MD, April 2007).

3. T.K. Ghosh et al., "Quick Dissolving Oral Dosage Forms: Scientific and Regulatory Considerations from a Clinical Pharmacology and Biopharmaceuticals Perspective," in Drug Delivery to the Oral Cavity: Molecules to Market, T.K. Ghosh and W.R. Pfister, Eds. (CRC Press, New York, NY, 2005), pp. 337-356.

4. Luca Dobetti, Pharm. Technol. 25 (9) Drug Delivery Supplement, 44–50 (2001).

5. K. Deepak, Tablets and Capsules 7, 30–35 (2004).

6. W. Pfister and T.K. Ghosh, Pharm. Technol. 29 (10), 136–150 (2005).

7. B. Martineau, Drug Del. Technol. 9 (4), 36–38 (2009).

8. S.V. Sastry and J. Nyshasham, "Process Development and Scale-up of Oral Fast-dissolving Tablets," in Drug Delivery to the Oral Cavity: Molecules to Market, T.K. Ghosh and W.R. Pfister, Eds. (CRC Press, New York, 2005), pp. 311–336.

9. N. Sharma et al., Pharm. Technol. 27 (10), 10–13 (2003).

10. M.C. Meilgaard, G.V. Civille, B.T. Carr, Sensory Evaluation Techniques (CRC Press LLC, New York, NY, 3rd ed., 1999), pp. 369.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here